The overall trend of insiders is illustrated in the chart below:
General Motors Co. (GM): Director Thomas M. Schoewe Bought 3,800 Shares
Director of General Motors Co., Thomas M. Schoewe, bought 3,800 shares on 3/05/2012 at an average price of $25.62. General Motors Company is engaged in the designing, manufacturing and retailing of vehicles globally including passenger cars, crossover vehicles, and light trucks, sport utility vehicles, vans and other vehicles. General Motors has a market cap of $41.41 billion; its shares were traded at around $25.62 with a P/E ratio of 6.8 and P/S ratio of 0.3.
On February 16, General Motors Co. announced 2011 calendar-year net income attributable to common stockholders of $7.6 billion, or $4.58 per fully diluted share, up from $4.7 billion, or $2.89 per fully diluted share, in 2010. Revenue increased 11 percent to $150.3 billion, compared with $135.6 billion in 2010. Full-year earnings before interest and tax (EBIT) adjusted was $8.3 billion, compared with $7.0 billion in 2010.
Last week, Director Thomas M Schoewe bought 3,800 shares of GM stock.
Illinois Tool Works Inc. (ITW): Director James W. Griffith Bought 2,000 Shares
Director of Illinois Tool Works Inc., James W. Griffith, bought 2,000 shares on 3/01/2012 at an average price of $55.44. Illinois Tool Works Inc. manufactures and markets a variety of products and systems that provide specific, problem-solving solutions for a diverse customer base worldwide. Illinois Tool Works has a market cap of $26.85 billion; its shares were traded at around $55.44 with a P/E ratio of 14.7 and P/S ratio of 1.5. The dividend yield of Illinois Tool Works stocks is 2.6%. Illinois Tool Works had an annual average earnings growth of 8.2% over the past 10 years. GuruFocus rated Illinois Tool Works the business predictability rank of 3-star.
On January 31, Illinois Tool Works Inc. reported fourth quarter 2011 diluted income per share from continuing operations of $0.90, a 36 percent increase compared to the 2010 fourth quarter. Total revenues of $4.319 billion in the 2011 fourth quarter were 10.4 percent higher than the year-ago period.
Last week, Director James W. Griffith bought 2,000 shares of ITW stock. Director Kevin M. Warren bought 1,000 shares in February. Director Robert C. Mccormack sold 128,500 shares last week. Vice Chairman David C. Parry, Executive Vice President Craig A. Hindman, Chairman and CEO David B. Speer, and Senior Vice President and CFO Ronald D. Kropp sold shares in February.
Corning Inc. (GLW): Director Gordon Gund Bought 150,000 Shares
Director of Corning Inc., Gordon Gund, bought 150,000 shares on 3/06/2012 at an average price of $13.29. Corning Incorporated creates leading-edge technologies for the fastest-growing markets of the world's economy. Corning Inc. has a market cap of $19.78 billion; its shares were traded at around $13.29 with a P/E ratio of 7.4 and P/S ratio of 2.5. The dividend yield of Corning Inc. stocks is 2.3%. Corning Inc. had an annual average earnings growth of 8.6% over the past five years.
On January 25, Corning Incorporated announced its results for the fourth quarter and year-end of 2011. For the fourth quarter, sales were $1.9 billion, a decline of 9% sequentially, but a 7% increase year over year. Earnings per share were $0.31. Excluding special items, earnings per share were $0.33*, a decline from third-quarter EPS of $0.48 and $0.46 a year ago.
Last week, Director Gordon Gund bought 150,000 shares of GLW stock. Director John A. Canning Jr. bought 30,000 shares in October. Executive Vice President Lawrence D. Mcrae and Executive Vice President Joseph A. Miller sold shares in February and Director H. Onno Ruding sold 24,050 shares in November.
Valeant Pharmaceuticals International Inc. (VRX): Executive Vice President and CFO Howard Bradley Schiller Bought 27,800 Shares
Executive Vice President and CFO of Valeant Pharmaceuticals International Inc., Howard Bradley Schiller, bought 27,800 shares during the past week at an average price of $55.58. Valeant Pharmaceuticals International Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. Valeant Pharmaceuticals International Inc. has a market cap of $16.58 billion; its shares were traded at around $55.58 with a P/E ratio of 20 and P/S ratio of 6.7.
On February 27, Valeant Pharmaceuticals International Inc. reported results for the fourth quarter of 2011. Total reported revenue was $688.4 million in the fourth quarter of 2011 as compared to $514.6 million in the fourth quarter of 2010 primarily attributable to acquisitions completed in 2011 and the growth of key dermatology brands, partly offset by a negative foreign exchange impact. Product sales were $654.2 million in the fourth quarter of 2011, as compared to $488.7 million in the 2010 year quarter.
Last week, CFO Howard Bradley Schiller bought 9,200 shares of VRX stock. Executive Vice President Administration and CHCO Brian M. Stolz bought 2,400 shares in November. Global Head of R&D Susan Hall sold 16,120 shares last week.
Rayonier Inc. (RYN): Director C. David Brown II Bought 17,000 Shares
Director of Rayonier Inc., C. David Brown II, bought 17,000 shares on 3/02/2012 at an average price of $45.04. Rayonier Inc., including its subsidiaries, is a international forest products company primarily engaged in the trading, merchandising and manufacturing of logs, timber and wood products, and in the production and sale of high-value-added specialty pulps. Rayonier Inc. has a market cap of $5.4 billion; its shares were traded at around $45.04 with a P/E ratio of 21.1 and P/S ratio of 3.6. The dividend yield of Rayonier Inc. stocks is 3.6%. Rayonier Inc. had an annual average earnings growth of 13.4% over the past 10 years. GuruFocus rated Rayonier Inc. the business predictability rank of 2.5-star.
On January 24, Rayonier Inc. reported fourth quarter net income of $56 million, or 45 cents per share, compared to $59 million, or 48 cents per share, in the prior year period. Full year 2011 net income totaled $276 million, or $2.20 per share, compared to $218 million, or $1.79 per share, in 2010.
Last week, Director C. David Brown II bought 17,000 shares of RYN stock. President and COO Paul G. Boynton, Senior Vice President, CAO and Corporate Secretary W. Edwin Frazier III, Senior Vice President Real Estate Charles Margiotta, and Senior Vice President and CFO Hans E. Vandennoort sold shares in December.